Shares are trading at $1.44 which is quite a bit below $1.76, the stock’s 50 day moving average and which is marginally higher than the 200 day moving average of $1.43. The 50 day moving average was down $-0.32 and the 200 day average went up $0.01 or +0.50%. Trading volume for Aralez Pharmaceuticals Inc. was 351K on Tuesday. Volume was down 48.71% under the stocks average daily volume.
Investors are a little more bullish recently at least if you consider the change in short interest. The firm realized a fall in short interest of -0.83% as of October 13, 2017 from the last reporting period. Short shares fell 27,249 over that period. Days to cover decreased from 3.0 to 3.0 and the percentage of shorted shares is 0.05% as of October 13.
Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) has been the object of insider selling activity recently. James Patrick Tursi, Chief Medical Officer let go of $24,900 worth of shares at an average price of $2.50 on Mon the 2nd. That brings the Chief Medical Officer’s holdings to $643,375 per an SEC filing yesterday.
These firms have modified their investment in ARLZ. As of the end of the quarter Jw Asset Management, LLC had disposed of a total of 1,112,785 shares trimming its stake by 77.7%. The value of the investment in ARLZ went from $3,065,000 to $432,000 decreasing 85.9% for the reporting period. As of quarter end Ubs Group Ag had sold 627 shares trimming its position 9.5%. The value of the total investment in Aralez Pharmaceuticals Inc. decreased from $14,000 to $8,000 a change of 42.9% quarter to quarter.
Nwam LLC trimmed its position by selling 15,100 shares a decrease of 35.9%. Nwam LLC now holds 27,000 shares with a value of $36,000. The value of the position overall is down by 60.0%. As of quarter end Cutler Group LP had sold a total of 8,704 shares trimming its holdings by 93.6%. The value of the investment in (ARLZ) went from $12,000 to $1,000 a change of $11,000 quarter over quarter.
As of the last earnings report the EPS was $-1.63 and is projected to be $-1.62 for the current year with 66,848,000 shares outstanding. Next quarter’s EPS is estimated at $-0.38 with next year’s EPS projected to be $-1.04.
Aralez Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada, Ireland, and the United States. The company engages in acquiring, developing, and commercializing products primarily in cardiovascular disease, pain, and other specialty areas. It offers Fibricor, a fenofibric acid for the treatment of severe hypertriglyceridemia; Cambia, a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks with or without aura in adults; Fiorinal and Fiorinal C for the relief of tension type headaches; Soriatane, a retinoid, an aromatic analog of vitamin A for the treatment of severe psoriasis and other disorders of keratinization; and Bezalip SR, a pan-peroxisome proliferator-activated receptor activator to treat hyperlipidemia, as well as to increase insulin sensitivity and decrease blood glucose levels for the patients with metabolic syndrome. The company also markets NeoVisc, a sodium hylauronic solution; Uracyst, a sodium chondroitin sulfate; Durela, a tramadol hydrochloride; Proferrin, a heme iron polypeptide; Resultz, a isopropyl myristate; Collatamp G, a collagen-gentamycin; and a portfolio of eight products targeted for the areas of gastroenterology and women’s health. In addition, it develops YOSPRALA 81/40 and 325/40 for secondary prevention of cardiovascular and cerebrovascular disease in patients at risk for gastric ulcers, which have completed Phase III clinical development in the United States; and Bilastine, an antihistamine drug for the treatment of allergic rhinoconjunctivitis and urticaria. Further, the company’s out-licensed products include VIMOVO for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers; and Treximet, a migraine medicine. Aralez Pharmaceuticals Inc. is headquartered in Milton, Canada. Aralez Pharmaceuticals Inc. .